Back to top
more

Repligen (RGEN)

(Real Time Quote from BATS)

$161.08 USD

161.08
382,780

-0.59 (-0.37%)

Updated Aug 5, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations

by Zacks Equity Research

Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.

Ekta Bagri headshot

3 Biotech Stocks Poised to Gain in the Second Half of 2021

by Ekta Bagri

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

by Zacks Equity Research

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.

Sanghamitra Saha headshot

Bet on Rising P/E Investing With These Top 5 Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo

by Zacks Equity Research

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

Apellis (APLS) Up on Tie-up With Beam for Novel Therapies

by Zacks Equity Research

Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.

Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate

by Zacks Equity Research

Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.

Horizon (HZNP) Begins Phase II Study for Lupus Candidate

by Zacks Equity Research

Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.

Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study

by Zacks Equity Research

Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma

by Zacks Equity Research

Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.

BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism

by Zacks Equity Research

Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.

Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.

Roche's (RHHBY) BLA for PDS With Ranibizumab Accepted by FDA

by Zacks Equity Research

The FDA accepts and grants Priority Review to Roche's (RHHBY) application for Port Delivery System with ranibizumab for the treatment of nAMD.

Entera (ENTX) Up on Positive Results From Osteoporosis Drug

by Zacks Equity Research

Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.

Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

by Zacks Equity Research

Bayer (BAYRY) submits an sNDA in the United States and an MAA in Europe for the combo of copanlisib and rituximab to treat two types of cancer indication.

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

by Zacks Equity Research

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

Bristol Myers' (BMY) Onureg Gets European Commission Approval

by Zacks Equity Research

Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

by Zacks Equity Research

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

by Zacks Equity Research

Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

by Zacks Equity Research

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

by Zacks Equity Research

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

by Zacks Equity Research

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail

by Zacks Equity Research

Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.

RAPT Reports Positive Data From Atopic Dermatitis Study

by Zacks Equity Research

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.